Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.
Saved in:
| Title: | Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies. |
|---|---|
| Authors: | Brennan FR; Discovery Research, UCB Pharma, Slough, UK., Polli JR; Pharmacokinetic Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, MA, USA., Sathish J; Comparative Medicine and Drug Safety R&D, Pfizer, Pearl River, NY, USA., Ramones M; Biologics Research Center, Novartis Biomedical Research, Cambridge, MA, USA., Wolf B; Preclinical Safety, Translational Medicine, Novartis Biomedical Research, Basel, Switzerland., Schlothauer T; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany., Peters SJ; Discovery Research, UCB Pharma, Slough, UK., Maier CC; Non-clinical Safety, GSK, Collegeville, PA, USA., Ji C; Comparative Medicine and Drug Safety R&D, Pfizer, La Jolla, CA, USA., Wensel DL; ViiV Healthcare, Branford, CT, USA., Witcher D; Eli Lilly and Company, Indianapolis, IN, USA., Ryan PC; Immune Safety, Clinical Pharmacology and Safety Sciences, Biopharmaceutical R&D, AstraZeneca, Gaithersburg, MD, USA., Manetz TS; Immune Safety, Clinical Pharmacology and Safety Sciences, Biopharmaceutical R&D, AstraZeneca, Gaithersburg, MD, USA., Flora A; JAX Mice and Clinical Research Services, The Jackson Laboratory, Bar Harbor, ME, USA., Soper B; JAX Mice and Clinical Research Services, The Jackson Laboratory, Bar Harbor, ME, USA., Fogal B; Boehringer Ingelheim Pharmaceuticals Inc., Nonclinical Drug Safety, Ridgefield, CT, USA., Dzielak L; Boehringer Ingelheim Pharmaceuticals Inc., Nonclinical Drug Safety, Ridgefield, CT, USA., Wang X; Amgen Research, Amgen Inc, South San Francisco, CA, USA., Shastri PN; Johnson & Johnson Innovative Medicine, Spring House, PA, USA., Price K; Johnson & Johnson Innovative Medicine, Spring House, PA, USA., Doyle M; Bristol-Myers Squibb, Princeton, NJ, USA., Sharda N; Bristol-Myers Squibb, Princeton, NJ, USA., Struthers M; Bristol-Myers Squibb, Princeton, NJ, USA., Brinkhaus M; argenx, Ghent, Belgium., Balbino B; argenx, Ghent, Belgium., Stefanich E; Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USA., Honda M; Chugai Pharmaceutical Co., Ltd, Kanagawa, Japan., Andersen JT; Department of Immunology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), Oslo Science Park, Oslo, Norway., Mitchell-Ryan S; The Health and Environmental Sciences Institute, Washington, DC, USA., Humphreys DP; Discovery Research, UCB Pharma, Slough, UK. |
| Source: | MAbs [MAbs] 2025 Dec; Vol. 17 (1), pp. 2505092. Date of Electronic Publication: 2025 Jul 07. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1942-0870 |
|---|---|
| DOI: | 10.1080/19420862.2025.2505092 |
